Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc.TARS · Entity 1836 | CHIEF MEDICAL OFFICER | December 20, 2023 | December 22, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tarsus Pharmaceuticals, Inc.
Report date December 20, 2023 · Filed December 22, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,251 |
Reported balance
After 2023-12-20 transaction · row 1
1 source rowRow 1 · 2023-12-20 · Sale · Disposed 2,252 · Balance 2,251 F1: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 20, 2023 Filed Dec 22, 2023 22:32 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 2,252 | $20.00 | $45,040.00 |
DisclosureSEC source: 0001661539-23-000008 · wk-form4_1703284363.xml · nonDerivative · entry 1 Trevejo Jose M. · CIK 0001661539 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,251 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2023. Read SEC document |
| October 05, 2023 Filed Oct 6, 2023 21:21 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 1,604 | $18.00 | $28,872.00 |
DisclosureSEC source: 0001661539-23-000006 · wk-form4_1696627288.xml · nonDerivative · entry 1 Trevejo Jose M. · CIK 0001661539 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,503 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2023. Read SEC document |
| March 23, 2023 Filed Mar 24, 2023 00:02 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 465 | $12.15 | $5,649.75 |
DisclosureSEC source: 0001661539-23-000004 · wf-form4_167961616570410.xml · nonDerivative · entry 3 Trevejo Jose M. · CIK 0001661539 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,107 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 22, 2023 Filed Mar 24, 2023 00:02 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 529 | $12.64 | $6,686.56 |
DisclosureSEC source: 0001661539-23-000004 · wf-form4_167961616570410.xml · nonDerivative · entry 2 Trevejo Jose M. · CIK 0001661539 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,572 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 21, 2023 Filed Mar 24, 2023 00:02 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 519 | $12.89 | $6,689.91 |
DisclosureSEC source: 0001661539-23-000004 · wf-form4_167961616570410.xml · nonDerivative · entry 1 Trevejo Jose M. · CIK 0001661539 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,101 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 20, 2023 Filed Mar 21, 2023 23:10 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 530 | $12.61 | $6,683.30 |
DisclosureSEC source: 0001661539-23-000002 · wf-form4_167944023837852.xml · nonDerivative · entry 2 Trevejo Jose M. · CIK 0001661539 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,620 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 23:10 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 504 | $13.28 | $6,693.12 |
DisclosureSEC source: 0001661539-23-000002 · wf-form4_167944023837852.xml · nonDerivative · entry 1 Trevejo Jose M. · CIK 0001661539 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,150 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 16, 2023 Filed Mar 17, 2023 22:18 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 499 | $13.43 | $6,701.57 |
DisclosureSEC source: 0001209191-23-019880 · doc4.xml · nonDerivative · entry 2 Trevejo Jose M. · CIK 0001661539 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,654 F3 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 22:18 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 7,549 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-019880 · doc4.xml · derivative · entry 3 Trevejo Jose M. · CIK 0001661539 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,648 Underlying: Common Stock · 7,549 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F5 · derivative.exercise_date: RSU granted on February 1, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. F5 · derivative.expiration_date: RSU granted on February 1, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 22:18 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 7,549 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-019880 · doc4.xml · nonDerivative · entry 1 Trevejo Jose M. · CIK 0001661539 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). F2 · balance_after: includes 1,604 shares acquired under the Issuer's employee stock purchase plan on December 31, 2022. Read SEC document |
| March 08, 2023 Filed Mar 11, 2023 00:28 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 30,792 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-018003 · doc4.xml · derivative · entry 2 Trevejo Jose M. · CIK 0001661539 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,792 Underlying: Common Stock · 30,792 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026, and 2027, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026, and 2027, subject to the Reporting Person's continuous service. Read SEC document |
| March 08, 2023 Filed Mar 11, 2023 00:28 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 45,459 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001209191-23-018003 · doc4.xml · derivative · entry 1 Trevejo Jose M. · CIK 0001661539 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,459 Underlying: Common Stock · 45,459 shares Expires 2033-03-08 F1 · derivative.exercise_date: 25% of the option shares shall vest on March 8, 2024, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the Reporting Person's continuous service. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 22:36 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 30,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001661539-22-000005 · wf-form4_164392778280060.xml · derivative · entry 2 Trevejo Jose M. · CIK 0001661539 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,197 Underlying: Common Stock · 30,197 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 22:36 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantEmployee Stock Option (right to buy) · Derivative | 116,424 | $0.00 Strike: $20.64 | $0.00 |
DisclosureSEC source: 0001661539-22-000005 · wf-form4_164392778280060.xml · derivative · entry 1 Trevejo Jose M. · CIK 0001661539 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,424 Underlying: Common Stock · 116,424 shares Expires 2032-01-31 F1 · derivative.exercise_date: 25% of the option shares shall vest on February 1, 2023, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the Reporting Person's continuous service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.